April 24, 2024 11:08 AM EDTUpdated 11:57 AM

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Jared Whitlock

Features Editor

Lia DeGroot

Almost 20 biopharma and life sciences companies have registered to lobby on a bill that could ban US companies from working with Chinese life sciences …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Jared Whitlock

Features Editor

Lia DeGroot

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

Features Editor

Sign up to read this article for free.

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues